RWD results reaffirm Leclaza’s efficacy in practice
By Chon, Seung-Hyun | translator Kim, Jung-Ju
23.05.22 15:34:55
가나다라
0
First real-world data since its release was published in Lung Cancer
“Confirmed consistent efficacy and safety in 103 patients”
“Showed effect in patients with brain metastasis...dose reduction did not reduce effect”
▲Professor Lim Sun Min (right) and Professor Beung-Chul Ahn (left) are presenting Leclaza study results
Study results that confirm the efficacy and safety of Yuhan Corp's new anticancer drug ‘Leclaza’ in the real world has been released.
Lim Sun Min, Professor of Oncology at Yonsei Cancer Center, and Beung-Chul Ahn, Professor of Oncology at the National Cancer Center, met with reporters at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association head office in Seocho-gu, Seoul on the 22nd to introduce the real-world data (RWD) that confirms the efficacy and safety of Leclaza in practice. This was the first-ever real-world study results announced since Leclaza’s approval, and was published in the journal, Lung Cancer.
Leclaza is an NSCLC treatment that was app
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)